In conclusion, this review highlights the lack of experimental psychopathology laboratory studies among individuals of non-European ancestry with AUD and the near absence of subjects of non-European ancestry in clinical trials examining pharmacologic treatments for AUD. We emphasize the need for pharmacogenetic studies that address the role of ethnic diversity to contribute to inclusive healthcare and personalized medicine for the treatment of AUD.
